Entrada Therapeutics Statistics
Share Statistics
Entrada Therapeutics has 37.42M shares outstanding. The number of shares has increased by 11.48% in one year.
| Shares Outstanding | 37.42M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.2% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 21.80M |
| Failed to Deliver (FTD) Shares | 24.74K |
| FTD / Avg. Volume | 17.98% |
Short Selling Information
The latest short interest is 1.66M, so 4.45% of the outstanding shares have been sold short.
| Short Interest | 1.66M |
| Short % of Shares Out | 4.45% |
| Short % of Float | 7.67% |
| Short Ratio (days to cover) | 15.27 |
Valuation Ratios
The PE ratio is -74.6 and the forward PE ratio is -6.5.
| PE Ratio | -74.6 |
| Forward PE | -6.5 |
| PS Ratio | 3.87 |
| Forward PS | 16.6 |
| PB Ratio | 2.06 |
| P/FCF Ratio | 3.72 |
| PEG Ratio | n/a |
Enterprise Valuation
Entrada Therapeutics Inc. has an Enterprise Value (EV) of 566.96M.
| EV / Earnings | -84.81 |
| EV / Sales | 4.39 |
| EV / EBITDA | -1766.23 |
| EV / EBIT | -179.3 |
| EV / FCF | 4.23 |
Financial Position
The company has a current ratio of 2.33, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.33 |
| Quick Ratio | 2.33 |
| Debt / Equity | 0.03 |
| Total Debt / Capitalization | 3.16 |
| Cash Flow / Debt | 17.68 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.03% and return on capital (ROIC) is 0.56%.
| Return on Equity (ROE) | -0.03% |
| Return on Assets (ROA) | -0.01% |
| Return on Capital (ROIC) | 0.56% |
| Revenue Per Employee | 728.89K |
| Profits Per Employee | -37.77K |
| Employee Count | 177 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 18.74M |
| Effective Tax Rate | 1.55 |
Stock Price Statistics
The stock price has increased by 26.92% in the last 52 weeks. The beta is -0.27, so Entrada Therapeutics 's price volatility has been lower than the market average.
| Beta | -0.27 |
| 52-Week Price Change | 26.92% |
| 50-Day Moving Average | 18.33 |
| 200-Day Moving Average | 15.62 |
| Relative Strength Index (RSI) | 41.26 |
| Average Volume (20 Days) | 137.59K |
Income Statement
In the last 12 months, Entrada Therapeutics had revenue of $129.01M and earned -$6.68M in profits. Earnings per share was $-0.2.
| Revenue | 129.01M |
| Gross Profit | 29.13M |
| Operating Income | -3.16M |
| Net Income | -6.68M |
| EBITDA | -321.00K |
| EBIT | -3.16M |
| Earnings Per Share (EPS) | -0.2 |
Balance Sheet
The company has $67.60M in cash and $68.23M in debt, giving a net cash position of -$628.00K.
| Cash & Cash Equivalents | 67.60M |
| Total Debt | 68.23M |
| Net Cash | -628.00K |
| Retained Earnings | -194.97M |
| Total Assets | 554.59M |
| Working Capital | 394.73M |
Cash Flow
In the last 12 months, operating cash flow was $139.80M and capital expenditures -$5.61M, giving a free cash flow of $134.19M.
| Operating Cash Flow | 139.80M |
| Capital Expenditures | -5.61M |
| Free Cash Flow | 134.19M |
| FCF Per Share | 4.06 |
Margins
Gross margin is 22.58%, with operating and profit margins of -2.45% and -5.18%.
| Gross Margin | 22.58% |
| Operating Margin | -2.45% |
| Pretax Margin | 9.34% |
| Profit Margin | -5.18% |
| EBITDA Margin | -0.25% |
| EBIT Margin | -2.45% |
| FCF Margin | 104.01% |
Dividends & Yields
TRDA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.13% |
| FCF Yield | 20.28% |
Analyst Forecast
The average price target for TRDA is $28, which is 58.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $28 |
| Price Target Difference | 58.4% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 4.33 |
| Piotroski F-Score | 4 |